COVID-19 treatments: research and development
The European Medicines Agency (EMA) is interacting with developers of potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.
EMA is providing guidance to assist developers of potential COVID-19 treatments to prepare for eventual applications for marketing authorisation.
The outcome of any consultation or advice from EMA is not binding on developers.
Product | Developer | Therapeutic class/drug type | Development stage at time of guidance |
---|---|---|---|
A64-DP | BCN Peptides SA | Immunomodulator | Non-clinical phase |
Acalabrutinib | Acerta Pharma BV / AstraZeneca | Immunomodulator | Clinical phase |
Anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin | Alliance hyperimmune project (Biotest AG, Bio Products Laboratory, LFB, Octapharma, CSL Behring and Takeda) | Antiviral | Clinical phase |
APN01 | Apeiron Biologics | Immunomodulator | Clinical phase |
Apremilast | Amgen Europe BV | Immunomodulator | Clinical phase |
AZD7442 | AstraZeneca | Antiviral (monoclonal antibody) | Non-clinical phase |
Baricitinib | Eli Lilly | Immunomodulator | Clinical phase |
CD24Fc | Oncoimmune Inc | Immunomodulator | Clinical phase |
CHAG-COVID19-CA | ChimAgents | Challenge agent for human infection models | Non-clinical phase |
Chloroquine | Oxford University | Other therapeutics | Clinical phase |
Chloroquine and hydroxychloroquine cyclops DPI | PureIMS | Other therapeutics | Clinical phase |
Copper chloride | ACOM | Antiviral | Clinical phase |
CT-P59 | Celltrion | Antiviral (monoclonal antibody) | Non-clinical phase |
Danoprevir | Ascletis Pharmaceuticals Co Ltd | Antiviral | Clinical phase |
Eculizumab | Alexion | Immunomodulator | Clinical phase |
Emapalumab and anakinra | Swedish Orphan Biovitrum AB (SOBI) | Immunomodulator | Clinical phase |
FAV00B | Farmak International Holding GmbH | Antiviral | Non-clinical phase |
Favipiravir | Glenmark Pharmaceuticals Ltd | Antiviral | Clinical phase |
Gimsilumab | Roivant | Immunomodulator | Clinical phase |
Kamada Anti-SARS-CoV-2 | Kamada Ireland Ltd | Immunoglobulin | Non-clinical phase |
Larifan Plus | Auramed Ltd | Antiviral | Non-clinical phase |
LY-CoV555 (LY3819253) and LY-CoV016 (LY3832479) | Eli Lilly | Antiviral (monoclonal antibody) | Non-clinical phase |
M5049 | Merck Healthcare | Immunomodulator | Non-clinical phase |
Mavrilimumab | Kiniksa Pharmaceuticals | Immunomodulator | Clinical phase |
Meplazumab | Jiangsu Pacific Meinuoke Biopharmaceutical Co Ltd | Antiviral (monoclonal antibody) | Clinical phase |
MK-4482 | Ridgeback Biotherapeutics LP/Merck Sharp & Dohme (Europe) Inc | Antiviral | Non-clinical phase |
Otilimab | GSK | Immunomodulator | Clinical phase |
PF-07304814 | Pfizer | Antiviral | Non-clinical phase |
Raloxifene | Dompé | Antiviral | Non-clinical phase |
Ravulizumab | Alexion | Other therapeutics | Clinical phase |
RBT-9 | Renibus Therapeutics Inc | Antiviral | Clinical phase |
REGN10933, REGN10987, REGN10989 | Regeneron UK | Antiviral (monoclonal antibody) | Non-clinical phase |
Remdesivir | Gilead | Antiviral | Clinical phase |
RESP301 | Thirty Respiratory Limited (30 Technology) | Antiviral | Non-clinical phase |
Sarilumab | Sanofi Aventis | Immunomodulator | Clinical phase |
Siltuximab | EUSApharma | Immunomodulator | Clinical phase |
Tocilizumab | Roche | Immunomodulator | Clinical phase |
UNI911 | Union Therapeutics | Antiviral | Clinical phase |
2703 | Vir Biotechnology/GSK | Antiviral (monoclonal antibody) | Clinical phase |
SNG001 | Synairgen Research Limited | Immunomodulator | Clinical phase |
VRP-033 | Venus Pharma GmbH | Immunomodulator | Non-clinical phase |
BRII-196, BRII-198 | Brii Biosciences | Antiviral (monoclonal antibody) | Non-clinical phase |
SCTA01 | Sinocelltech Ltd. | Antiviral (monoclonal antibody) | Clinical phase |
Itolizumab | Biocon Biologics Limited | Immunomodulator (monoclonal antibody) | Clinical phase |
BI 764198 | Boehringer Ingelheim International GmbH | Other therapeutic | Clinical phase |
4P021 | 4P-Pharma | Antiviral | Non-clinical phase |
Masitinib mesylate | AB Science | Antiviral | Non-clinical phase |
EX-14870 | Boehringer Ingelheim International BmBH | Antiviral | Non-clinical phase |
2Deo | Dermin Sp. Z.0.0 | Other therapeutic | Non- Clinical Phase |
Emiplacel | Biopharma Excellence GmbH | Other therapeutic | Clinical Phase |
AT-527 | Roche | Antiviral | Clinical phase |
ABBV-47D11 | AbbVie | Antiviral | Clinical phase |
Aviptadil | Relief Therapeutics Holding S.A | Other therapeutics | Clinical Phase |
AR-711 | Aridis Pharmaceuticals, Inc. | Antiviral (monoclonal antibody) | Non-clinical phase |
Colchicine | Pharmascience Inc. (PMS) / Montreal Health Institute (MHI) | Immunomodulator | Clinical Phase |
CoviFab | Inmunova S.A. / mAbxience | Antiviral | Clinical phase |
IgM enriched human immune globulin (Trimodulin) (BT588) | Biotest AG | Antiviral | Clinical phase |
This information should not be read as an endorsement of any medicine.
Information on ongoing clinical trials for COVID-19 treatments in the European Economic Area (EEA) is available in the EU Clinical Trials Register (EU CTR):
Users can find information on:
- phase II to phase IV adult clinical trials for COVID-19 treatments where the investigator sites are in the EEA;
- any clinical trials in children with investigator sites in the EU and any trials that form part of a paediatric investigation plan, including those where the investigator sites are outside the EU.
Phase I clinical trials conducted solely in adults are not made publicly available in the EU CTR.
For more information on the EU CTR and how clinical trials are authorised and overseen in the EEA, see: